Newsroom

November 3, 2021, Sera announced the publication of a rigorous  validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the company’s PreTRM® test.

Nov. 2, 2021, Sera announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, leading organizations all geared to empowering and supporting families impacted by preterm birth.

October 27, 2021- The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time.

September 28, 2021- Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

September 15, 2021- Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company.

September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.

September 13, 2021- Sera will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021 at 8:15 a.m. Eastern Time.

August 30, 2021- Sera announced financial results for the second quarter ended June 30, 2021.

August 17, 2021- Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

July 14, 2021 – Sera today announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share.